VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - May 11, 2006) - Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, reported today in its first quarter 2006 operating results that it continued to achieve important milestones in its drug development programs. Achievements during the quarter included: Publication of results from a Phase Ia human clinical trial showing AL-208 to be safe and well tolerated in the target population for the treatment of mild cognitive impairment (MCI) associated with coronary artery bypass graft surgery (CABG).
